<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191474</url>
  </required_header>
  <id_info>
    <org_study_id>CCTG 602</org_study_id>
    <nct_id>NCT03191474</nct_id>
  </id_info>
  <brief_title>Linkage of Transgender Individuals to PrEP</brief_title>
  <official_title>CCTG 602: Linkage of Transgender Individuals to PrEP, A Multicenter Trial of the California Collaborative Treatment Group (CCTG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Los Angeles LGBT Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CCTG 602 is a multisite demonstration project to evaluate the effectiveness of facilitated&#xD;
      linkage to PrEP using a community-based transgender PrEP outreach worker (T-POWr) versus&#xD;
      standard of care (SOC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 500 self-identified transgender / gender non-conforming persons seeking daily&#xD;
      Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV will be enrolled into this study.&#xD;
      Each participant will be followed up to 28 weeks after enrollment. The primary endpoint,&#xD;
      successful linkage to a PrEP evaluation visit, will be measured after 30 days of enrollment.&#xD;
&#xD;
      Participants expressing interest in PrEP will be referred to the regional transgender PrEP&#xD;
      outreach work (T-POWr) via phone call. Enrolled participants will be randomized (1:1) to&#xD;
      either SOC PrEP linkage vs T-POWr facilitated PrEP linkage. Participants randomized into the&#xD;
      SOC Arm will receive an HIV risk assessment, PrEP education, and an appointment for a linkage&#xD;
      visit. Participants randomized into the T-POWr arm will receive SOC and a thorough&#xD;
      client-centered case management evaluation that will assess needs including access to health&#xD;
      insurance, general health care, assessment of current hormone administration, housing, mental&#xD;
      health care, domestic violence care, substance use treatment, and other services.&#xD;
&#xD;
      Participants will be contacted at Week 4 to verify linkage, and at Weeks 16 and 28 to assess&#xD;
      PrEP and HIV status, and access to referred services.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2017</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Facilitated Linkage</measure>
    <time_frame>Baseline up to Week 28</time_frame>
    <description>To evaluate the effectiveness of a T-POWr intervention to effectively link transgender / gender non-conforming persons to a PrEP evaluation visit.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>HIV Seronegativity</condition>
  <condition>Linkage</condition>
  <arm_group>
    <arm_group_label>Standard of Care Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive standard of care HIV risk assessment, PrEP education, and an appointment for a PrEP evaluation visit at an affiliated clinic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-POWr Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the same HIV risk assessment, PrEP education, and appointment for a PrEP evaluation visit as the Control Arm. Participants in the Intervention Arm will also receive a thorough client-centered case management evaluation that will assess needs including access to health insurance, general health care, assessment of current hormone administration, housing, mental health care, domestic violence care, substance use treatment, and other services.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>T-POWr Intervention</intervention_name>
    <description>All participants will be asked to complete a secure confidential online survey focusing on needs assessment.&#xD;
Participants in the T-POWr Intervention Arm will receive a client-centered case management consultation based on how the participant responds to the online survey. The T-POWr will refer participants to assistance services based on the needs assessment, including accessing general health care, health insurance, hormone replacement therapy, housing, mental health care, domestic violence care, substance use treatment, etc. Each resource is extensively vetted to assure a trans-friendly experience and will be tailored to each geographic area across the project enrollment sites. The study facilitates referrals for services but will not provide extensive and ongoing case management.</description>
    <arm_group_label>T-POWr Intervention Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Self-identifies as a transgender or gender non-conforming person&#xD;
&#xD;
          -  Self-identifies as HIV-negative or unknown status&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe active substance abuse or mental illness that the investigator feels will&#xD;
             interfere with the ability to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Transgender or Gender Non-conforming, defined as identifying with a gender different from sex assigned at birth.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheldon Morris, MD MPH</last_name>
    <role>Study Chair</role>
    <affiliation>CCTG, UCSD AVRC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Lesbian, Gay, Bisexual, and Transgender Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego AntiViral Research Center (AVRC)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 15, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Sheldon Morris</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>PrEP</keyword>
  <keyword>Pre-exposure Prophylaxis</keyword>
  <keyword>Truvada</keyword>
  <keyword>Client-centered case management</keyword>
  <keyword>Transgender</keyword>
  <keyword>Gender non-conforming</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

